Ignite Creation Date:
2024-05-06 @ 8:26 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02732119
Status:
COMPLETED
Last Update Posted:
2021-05-05
First Post:
2016-04-04
Brief Title:
Study of Ribociclib With Everolimus Exemestane in HR HER2- Locally AdvancedMetastatic Breast Cancer Post Progression on CDK 46 Inhibitor
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CLEE011XUS29
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None